- Home
- SAFE vs VOR Comparison
SAFE vs VOR Comparison
Compare SAFE & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | VOR |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SAFE | VOR |
|---|---|---|
| Price | $16.19 | $22.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $19.00 | ★ $45.33 |
| AVG Volume (30 Days) | 274.0K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $20.01 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $1.62 |
| 52 Week High | $17.45 | $49.95 |
Technical Indicators
Market Signals| Indicator | SAFE | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 66.20 |
| Support Level | $13.99 | $11.62 |
| Resistance Level | $16.54 | $22.22 |
| Average True Range (ATR) | 0.49 | 1.51 |
| MACD | -0.07 | 0.20 |
| Stochastic Oscillator | 25.00 | 86.09 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.